Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases

Asghar Fallah; Ali Sadeghinia; Houman Kahroba; Amin Samadi; Hamid Reza Heidari; Behzad Bradaran; Sirous Zeinali; Ommoleila Molavi

doi:10.1016/j.biopha.2018.12.022

Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases

Biomed Pharmacother. 2019 Feb:110:775-785. doi: 10.1016/j.biopha.2018.12.022. Epub 2018 Dec 13.

Authors

Asghar Fallah¹, Ali Sadeghinia², Houman Kahroba³, Amin Samadi⁴, Hamid Reza Heidari⁵, Behzad Bradaran⁶, Sirous Zeinali⁷, Ommoleila Molavi⁸

Affiliations

¹ Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
² Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
³ Molecular Medicine Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
⁴ Department of Chemical and Materials Engineering, University of Alberta, Edmonton, Canada.
⁵ Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
⁶ Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
⁷ Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
⁸ Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; Molecular Medicine Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: omolavi@ualberta.ca.

PMID: 30554116
DOI: 10.1016/j.biopha.2018.12.022

Abstract

Angiogenesis is a critical step in the progression of almost all human malignancies and some other life-threatening diseases. Anti-angiogenic therapy is a novel and effective approach for treatment of angiogenesis-dependent diseases such as cancer, diabetic retinopathy, and age-related macular degeneration. In this article, we will review the main strategies developed for anti-angiogenic therapies beside their clinical applications, the major challenges, and the latest advances in the development of anti-angiogenesis-based targeted therapies.

Keywords: Angiogenesis-dependent diseases; Anti-angiogenesis; Anti-angiogenic therapeutics; Cancer; VEGF–VEGFR system receptors.

Publication types

Review

MeSH terms

Angiogenesis Inducing Agents / metabolism
Angiogenesis Inhibitors / administration & dosage*
Angiogenesis Inhibitors / metabolism
Animals
Cytokines / antagonists & inhibitors
Cytokines / metabolism
Drug Delivery Systems / methods*
Humans
Neovascularization, Pathologic / drug therapy*
Neovascularization, Pathologic / metabolism
Signal Transduction / drug effects*
Signal Transduction / physiology
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Vascular Endothelial Growth Factor A / metabolism

Substances

Angiogenesis Inducing Agents
Angiogenesis Inhibitors
Cytokines
VEGFA protein, human
Vascular Endothelial Growth Factor A